GHK-Cu: the repair molecule your body stops making

Your body already makes a copper-carrying molecule whose whole job is to help you repair — skin, tissue, the machinery that keeps you healing young. It’s called GHK-Cu. And here’s the part that should get your attention: you make less of it every year, and that drop-off lines up with almost everything we call ageing in skin.

The idea behind GHK-Cu is almost too good. Put the repair signal back, and the body remembers how to rebuild. There are real early signs it might do exactly that. If they hold up, this isn’t a moisturiser story. It’s a repair story.

What it could actually do for you

So what could it do? Two things, and they’re big.

It tells your skin to rebuild the scaffolding underneath — the collagen and elastin that keep it firm and springy — and it slows the enzymes that tear that scaffolding down. Build the structure up, slow the breakdown down: the exact two things that go wrong as skin ages, worked from both ends at once. That’s the picture two research reviews lay out — one from 2015 and a follow-up in 2018 — across a long list of cell and animal work.

In animal studies it also closes wounds faster. Stack that up and you’ve got a molecule that could help the body repair itself — about as close to the longevity dream as a single compound gets. That’s the upside, and it’s a genuinely exciting one.

Why the biology is worth the excitement

GHK-Cu was first pulled out of human blood back in the 1970s. The chemists who isolated it kept noticing the active molecule dragged a copper ion along with it — and the copper turned out not to be a passenger. It was the point. Strip the copper away and most of the effect goes with it.

That’s what makes GHK-Cu more interesting than the average serum ingredient. It isn’t a lab invention borrowed from somewhere else in biology. It’s a signal your own body already runs on — a tiny three-part peptide that grabs copper and, in the lab, switches on the repair programme inside skin cells. The idea more or less writes itself: hand the body back a repair signal it’s losing with age, in the exact form it already knows how to use.

The honest boundary

Now the clarity, because we won’t oversell this.

Most of what we know is from the lab, from animals, and from one researcher — Loren Pickart — who has spent forty years on this molecule. That’s a serious body of work. It’s also not the same thing as a dozen independent labs, with no stake in the answer, getting the same result.

The one time GHK-Cu skincare went through a proper randomised human trial — Miller and colleagues, 2006, thirteen patients after CO₂ laser resurfacing — the objective measures came back null. Blinded evaluators and a computer found no significant difference against placebo on redness, wrinkles, or skin quality. The one thing that moved was the patients’ own opinion of their skin (P=0.04). The machines couldn’t tell the two faces apart; the people could. Both readings are honest. They don’t tell the same story.

Twenty years on, a 2025 review asked the plainest question of all — does topical GHK even get through skin to where it’s supposed to work? — and concluded the published data is too thin to say either way. And the injectable version now sold in vials has essentially no human data at all: no pharmacokinetics, no safety file, no trial in any indication.

So this is early. The honest position is hope with your eyes open. The potential is real, the early signals are real, and the studies to prove it simply haven’t been done yet. If it turns out as good as the early work hints, it could be transformational. That if is the whole game.

Where the regulators sit

GHK-Cu isn’t on the FDA’s July 2026 PCAC wave — that round covers a different set of peptides, confirmed against the April 2026 Federal Register notice. It’s scheduled for the next review instead, before the end of February 2027 — and specifically the injectable form, which is the one sold off-label. What a PCAC review actually decides is a longer story, told in what a PCAC review actually is. The short version: the regulators are about to take a formal look at the exact form with the least human evidence behind it.

Anti-doping is simpler. GHK-Cu isn’t named on the WADA prohibited list. If you’re tested, check the current code on the day — that can move.

What happens next

The potential is real. The proof isn’t finished. And the version worth being excited about looks nothing like a vial off a research-chemical site.

It looks like a physician writing a prescription against a real indication, a licensed US pharmacy compounding it, and an assay on every batch before it ships. Wolverine Health exists to be exactly that — the legitimate version of a thing people are already buying the illegitimate way. It can’t open until the regulation catches up, and that’s the honest reason it hasn’t yet. The date circled on the wall is that February 2027 PCAC session on injectable GHK-Cu. Leave your email and we’ll tell you the day the door opens.